(Bloomberg) -- GlaxoSmithKline Plc was the drug
industry's top advertiser last year, promoting its asthma and
diabetes treatments to patients and doctors. Information the
company didn't make well known is now drawing more attention.
London-based Glaxo knew its Avandia diabetes pill posed a
risk for heart and circulatory complications as early as 1999,
when the medicine won U.S. approval. The cardiovascular concern
wasn't widely disseminated until May 21 when a Cleveland Clinic
Foundation analysis reported that Avandia may cause a 43 percent
higher risk of heart attacks than other drugs.
Read more at Bloomberg Exclusive News
industry's top advertiser last year, promoting its asthma and
diabetes treatments to patients and doctors. Information the
company didn't make well known is now drawing more attention.
London-based Glaxo knew its Avandia diabetes pill posed a
risk for heart and circulatory complications as early as 1999,
when the medicine won U.S. approval. The cardiovascular concern
wasn't widely disseminated until May 21 when a Cleveland Clinic
Foundation analysis reported that Avandia may cause a 43 percent
higher risk of heart attacks than other drugs.
Read more at Bloomberg Exclusive News
No comments:
Post a Comment